Wedbush Downgrades Fusion Pharmaceuticals to Neutral, Announces $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten downgraded Fusion Pharmaceuticals (NASDAQ:FUSN) from Outperform to Neutral and set a $24 price target.
March 19, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Fusion Pharmaceuticals was downgraded by Wedbush from Outperform to Neutral with a new price target of $24.
The downgrade from Outperform to Neutral by a reputable analyst could lead to mixed investor sentiment. While the establishment of a $24 price target suggests some upside potential, the downgrade itself may temper short-term bullishness.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100